Citadel Advisors - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 53 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$4,241,000
+1891.1%
2,009,747
+2636.8%
0.00%
Q1 2021$213,000
-15.1%
73,434
-37.5%
0.00%
Q4 2020$251,000
+15.1%
117,583
+234.0%
0.00%
Q3 2020$218,000
+96.4%
35,200
+105.2%
0.00%
Q2 2020$111,000
+85.0%
17,157
+68.4%
0.00%
Q4 2019$60,00010,1900.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q2 2020
NameSharesValueWeighting ↓
Eversept Partners, LP 522,042$1,117,1700.13%
XTX MARKETS LLC 26,041$56,0000.12%
Samsara BioCapital, LLC 300,000$642,0000.06%
Ikarian Capital, LLC 650,000$1,392,0000.06%
Opaleye Management Inc. 187,750$402,0000.05%
SABBY MANAGEMENT, LLC 108,026$231,0000.04%
Anson Funds Management LP 97,601$209,0000.04%
Virtu Financial LLC 83,221$178,0000.02%
GSA CAPITAL PARTNERS LLP 47,084$101,0000.02%
WEXFORD CAPITAL LP 19,512$42,0000.01%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders